Apoptosis
Read More about this categoryShow Less
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
Research Areas
- Caspase(145)
- Pyroptosis(42)
- 14.3.3 Proteins(1)
- Apoptosis Inducers(42)
- Bax(6)
- Bcl-2 Family(188)
- Bcl-xL(8)
- c-RET(8)
- IAP(33)
- KEAP1-Nrf2(90)
- MDM2(12)
- p53(154)
- PC-PLC(4)
- PKD(7)
- RasGAP (Ras- P21)(1)
- Survivin(13)
- Thymidylate Synthase(12)
- TNF-α(262)
- Other Apoptosis(877)
- APC(6)
- PD-1/PD-L1 interaction(132)
- ASK1(4)
- PAR4(2)
- RIP kinase(57)
- FKBP(25)
- Cuproptosis(4)
Products Related to Apoptosis(3394)
- GC72851BelapectinCAS: 1980787-47-0Purity: >99.00%
Belapectin (GR-MD-02) ist ein Galektin-3 (Gal-3)-Hemmer.
- GC72858Avenanthramide ACAS: 108605-70-5Purity: >99.00%
Avenanthramide A ist ein Ptolexin, das in Hafer (Avena sativa L.) vorkommt.
- GC72863PZ703b TFAPurity: >98.00%
PZ703b TFA ist ein Bcl-xl PROTAC Abbauprodukt, das Apoptose induziert und die Proliferation von Krebszellen für die Blasenkrebsforschung hemmt.
- GC72864PZ703b hydrochloridePurity: >99.00%
PZ703b hydrochloride ist ein Bcl-xl PROTAC-Abbau, der Apoptose induziert und die Proliferation von Krebszellen hemmt.
- GC72875Justicidin ACAS: 25001-57-4Purity: >99.00%
Justicidin A ist ein Naturprodukt, das aus Justicia procumbens isoliert werden könnte.
- GC72878UCD38B hydrochlorideCAS: 1115177-19-9Purity: >99.00%
UCD38B hydrochloride ist ein zellpermeanter, kompetitiver enzymatischer uPA-Inhibitor mit einem IC50-Wert von 7 μM.
- GC72892Oblimersen sodiumPurity: >98.00%
Oblimersen sodium ist ein BCL-2-Inhibitor, der auf BCL-2 RNA abzielt.
- GC72931HTH-01-091 TFAPurity: >98.00%
HTH-01-091 TFA ist ein potenter und selektiver mütterlicher embryonaler Leucin Zipper Kinase (MELK)-Hemmer mit einem IC50 von 10,5 nM.
- GC72985Z-LEVD-FMKCAS: 1135688-25-3Purity: >98.50%
Z-LEVD-FMK ist ein zelldurchlässiger Caspase-4-Hemmer.
- GC72991(Rac)-LisaftoclaxCAS: 2651980-10-6Purity: >98.00%
(Rac)-Lisaftoclax Rac-APG-2575 ist ein Bcl-2-Hemmer, der für die hämatologische Malignitätsforschung CN112898295A verwendet werden kann.
- GC73002Ganglioside GD3 diammoniumPurity: >98.00%
Ganglioside GD3 diammonium ist ein saures Glykosphingolipid.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC72835 | NSC260594 | 906718-66-9 | >96.00% | |
NSC260594 induziert Apoptose. | ||||
| GC72851 | Belapectin | 1980787-47-0 | >99.00% | |
Belapectin (GR-MD-02) ist ein Galektin-3 (Gal-3)-Hemmer. | ||||
| GC72858 | Avenanthramide A | 108605-70-5 | >99.00% | |
Avenanthramide A ist ein Ptolexin, das in Hafer (Avena sativa L.) vorkommt. | ||||
| GC72862 | Erasin | 2256056-21-8 | >95.00% | |
Erasin ist eine starke Erlotinib-Resistenz, die STAT3-Inhibitor mit IC50s von 9,7 und 24 μM gegen STAT3 bzw. STAT1 antagonisiert. | ||||
| GC72863 | PZ703b TFA | - | >98.00% | |
PZ703b TFA ist ein Bcl-xl PROTAC Abbauprodukt, das Apoptose induziert und die Proliferation von Krebszellen für die Blasenkrebsforschung hemmt. | ||||
| GC72864 | PZ703b hydrochloride | - | >99.00% | |
PZ703b hydrochloride ist ein Bcl-xl PROTAC-Abbau, der Apoptose induziert und die Proliferation von Krebszellen hemmt. | ||||
| GC72868 | AZA197 | 1249398-09-1 | >98.00% | |
AZA197 ist ein selektiver kleinmolekularer Inhibitor von Cdc42. | ||||
| GC72875 | Justicidin A | 25001-57-4 | >99.00% | |
Justicidin A ist ein Naturprodukt, das aus Justicia procumbens isoliert werden könnte. | ||||
| GC72878 | UCD38B hydrochloride | 1115177-19-9 | >99.00% | |
UCD38B hydrochloride ist ein zellpermeanter, kompetitiver enzymatischer uPA-Inhibitor mit einem IC50-Wert von 7 μM. | ||||
| GC72892 | Oblimersen sodium | - | >98.00% | |
Oblimersen sodium ist ein BCL-2-Inhibitor, der auf BCL-2 RNA abzielt. | ||||
| GC72910 | DD1 | 187585-11-1 | >99.00% | |
DD1, ein Proteasom-Inhibitor, zielt auf die Bax-Aktivierung und den Abbau von P70S6K während der Apoptose der akuten myeloischen Leukämie (AML) ab. | ||||
| GC72915 | (R)-MRT199665 | - | >98.00% | |
(R)-MRT199665 ist ein Isomer von MRT199665. | ||||
| GC72924 | PD173952 | 305820-75-1 | >99.00% | |
PD173952 ist ein Tyrosinkinasen-Inhibitor mit IC50s von 0.3, 1.7 und 6.6 nM gegen Lyn, Abl und Csk. | ||||
| GC72928 | DB818 | 790241-43-9 | >98.00% | |
DB818 ist ein starker Hemmer von Homeobox A9 (HOXA9). | ||||
| GC72929 | DB818 dihydrochloride | - | - | |
DB818 dihydrochloride ist die Didrochloridsalzform von DB818. | ||||
| GC72931 | HTH-01-091 TFA | - | >98.00% | |
HTH-01-091 TFA ist ein potenter und selektiver mütterlicher embryonaler Leucin Zipper Kinase (MELK)-Hemmer mit einem IC50 von 10,5 nM. | ||||
| GC72933 | LQZ-7F | 354543-09-2 | >97.00% | |
LQZ-7F, ein Survivin-Dimerisierungshemmer, induziert spontane Apoptose und synergiert mit Docetaxel in Prostatakrebszellen. | ||||
| GC72944 | MMRi64 | 430458-66-5 | >98.00% | |
MMRi64 stört Mdm2-MdmX-Interaktionen. | ||||
| GC72971 | INCB3619 | 791826-72-7 | >98.00% | |
INCB3619 ist ein selektiver und oral aktiver ADAM-Inhibitor mit IC50 von 22 nM bzw. 14 nM für ADAM10 bzw. ADAM117. | ||||
| GC72985 | Z-LEVD-FMK | 1135688-25-3 | >98.50% | |
Z-LEVD-FMK ist ein zelldurchlässiger Caspase-4-Hemmer. | ||||
| GC72991 | (Rac)-Lisaftoclax | 2651980-10-6 | >98.00% | |
(Rac)-Lisaftoclax Rac-APG-2575 ist ein Bcl-2-Hemmer, der für die hämatologische Malignitätsforschung CN112898295A verwendet werden kann. | ||||
| GC72994 | RAPTA-C | 372948-28-2 | >99.00% | |
RAPTA-C (Ru(η6-p-cymen)Cl2(pta)) wirkt als Krebs- und Angiogenetikum. | ||||
| GC73002 | Ganglioside GD3 diammonium | - | >98.00% | |
Ganglioside GD3 diammonium ist ein saures Glykosphingolipid. | ||||
| GC73016 | AZD4877 | 758722-49-5 | >98.00% | |
AZD4877 ist ein weiteres Isoster zu Ispinesib und auch ein Kinesinspindelprotein (Eg5)-Inhibitor mit IC50 von 2 nM. | ||||
